Bridge Point Capital and Saama Analytics Announced Strategic Partnership

Manhattan, New York, New York, November 11, 2021 – Bridge Point Capital (BPC) and Saama Analytics are pleased to announce that they have entered a global strategic partnership. This combination of BPC’s proprietary U.S. healthcare deal flow with Saama’s industry-leading AI clinical analytics platform has breakthrough potential.

Saama Analytics is an enterprise platform intended to assist medical companies in assessing business risk decisions. The company's platform offers data analytics services powered with big data, cloud and AI/ML aptitudes, enabling customers in life sciences, insurance, CPG and other industries to see around corners while making confident business decisions for efficient business outcomes.

Saama’s world-renowned Life Science Analytics Cloud puts real intelligence into drug discovery and development using AI and machine learning to streamline workflows, improve performance, and bring life-changing medical treatments to patients faster. LSAC brings all diverse data sources—EDC, CTMS, financials, ePRO, IVRS, labs, multiomics, biomarkers, real-world data, etc.—together into a unified model that accelerates clinical development outcomes. By offering oversight across more than 1,500 clinical studies, LSAC has become the platform of choice for more than 65 biopharmaceutical companies worldwide.

Saama has built long-lasting relationships with the most respected pharmaceutical companies, nonprofit organizations, universities, and government agencies in the world, by delivering game-changing solutions that improve clinical trial outcomes. Currently, Carlyle and Healthcare venture funds from Merck, Pfizer, Amgen, McKesson, and others announce strategic growth Investment of up to &430 million in Saama. These funds are embracing AI technologies for accelerating the delivery of safe and effective medical treatments.

“AI-driven analytics solutions are transforming the way that data is managed. We believe that Saama can play a crucial role in that transformation for the life sciences industry and more and more companies can benefit from their novel platforms,” said Mark Young, Co-founder & Co-CIO of Bridge Point Capital. The BPC-Saama partnership is indeed a powerful combination. BPC brings healthcare solutions with revolutionary technologies to both the US and Asian markets. Saama is the number one AI-powered clinical analytics cloud platform company delivering actionable business insights for life sciences. Having BPC as a strong strategic partner gives Saama more access to the global capital market.

About Bridge Point Capital:

Bridge Point Capital is a private equity firm based in New York, with a focus on U.S-Asia cross-border investments. We specialize in investing in disruptive mid- to late-stage healthcare companies that can benefit from penetrating the vast, yet unexplored Asian healthcare market. We aim to leverage our expertise in both healthcare and capital markets, to establish a lucrative investment platform for our investors.